Alembic Pharmaceuticals Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹184 Cr
QSept 2025
In Sept 2025, Alembic Pharmaceuticals (APLLTD) reported revenue ₹1,919 Cr and net profit ₹184 Cr — revenue +14.4% YoY. For annual financials, live price and key ratios, visit APLLTD share price.
APLLTD Quarterly Results — Revenue, Profit & EPS Highlights
Alembic Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View Alembic Pharmaceuticals yearly highs lows for the annual high/low range and current price position.
- Revenue of ₹1,919 Cr in Sept 2025 (+7.6% vs Mar 2025, +14.4% vs Sept 2024)
- Net Profit of ₹184 Cr in Sept 2025 (+17.2% vs Mar 2025, +20.3% vs Sept 2024)
- EBITDA of ₹324 Cr in Sept 2025 (+13.3% vs Mar 2025)
- Operating Margin of 17.0% in Sept 2025 (+2.0pp vs Mar 2025)
- Earnings Per Share of ₹9.40 in Sept 2025 (+17.8% vs Mar 2025)
Alembic Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
APLLTD quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,919 | 1,784 | 1,717 | 1,892 | 1,678 | 7.6% | 14.4% |
| Net Profit (₹ Cr) | 184 | 157 | 154 | 132 | 153 | - | - |
| EBITDA (₹ Cr) | 324 | 286 | 287 | 265 | 270 | - | - |
| EPS (₹) | 9.40 | 7.98 | 7.85 | 6.76 | 7.79 | - | - |
| Operating Margin (%) | 17.0% | 15.0% | 16.0% | 13.0% | 15.0% | - | - |
APLLTD Share Price Trend — 1-Year Movement Across Quarterly Results
Alembic Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices.
Revenue Trend (₹ Cr)
Dec 2025
1,892
Jun 2025
1,717
Mar 2025
1,784
Sept 2025
1,919
Net Profit Trend (₹ Cr)
Dec 2025
132
Jun 2025
154
Mar 2025
157
Sept 2025
184
Operating Margin Trend (%)
Dec 2025
13.0%
Jun 2025
16.0%
Mar 2025
15.0%
Sept 2025
17.0%
APLLTD vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Alembic Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹415,924.72 Cr | 1808.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 139.1 |
|
Divis Laboratories
Sept 2025 |
₹171,625.44 Cr | 6502.5 | 2,860 | 689 | +7.1% | - | 24.1% | 250.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹142,059.09 Cr | 4185.1 | 3,219 | 591 | +11.3% | - | 18.4% | 238.6 |
|
Dr Reddys Laborator…
Sept 2025 |
₹110,348.15 Cr | 1322.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 81.8 |
|
Cipla
Sept 2025 |
₹105,996.98 Cr | 1309.6 | 7,716 | 1,353 | +12.0% | - | 17.5% | 78.3 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores